Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent

[1] Pfister S(2008)BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas J Clin Invest 118 1739-1749

[2] Janzarik WG(2009)Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours Br J Cancer 101 722-733

[3] Remke M(2011)Analysis of BRAFV600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma Acta Neuropathol 121 397-405

[4] Ernst A(2011)Targeted therapy for BRAFV600E malignant astrocytoma Clin Cancer Res 17 7595-7604

[5] Werft W(2014)Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy BMC Cancer 14 258-1103

[6] Becker N(2014)Vemurafenib in pediatric patients with BRAFV600E mutated high grade gliomas Pediat Blood Cancer 61 1101-8677

[7] Toedt G(2008)Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas Cancer Res 68 8673-910

[8] Wittmann A(2013)BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma Acta Neuropathol 125 901-468

[9] Kratz C(2013)A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method Neuro Oncol 15 462-1268

[10] Olbrich H(2010)A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702) Neuro Oncol 12 1257-2638

[1] Pfister S(2008)BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas J Clin Invest 118 1739-1749

[2] Janzarik WG(2009)Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours Br J Cancer 101 722-733

[3] Remke M(2011)Analysis of BRAFV600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma Acta Neuropathol 121 397-405

[4] Ernst A(2011)Targeted therapy for BRAFV600E malignant astrocytoma Clin Cancer Res 17 7595-7604

[5] Werft W(2014)Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy BMC Cancer 14 258-1103

[6] Becker N(2014)Vemurafenib in pediatric patients with BRAFV600E mutated high grade gliomas Pediat Blood Cancer 61 1101-8677

[7] Toedt G(2008)Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas Cancer Res 68 8673-910

[8] Wittmann A(2013)BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma Acta Neuropathol 125 901-468

[9] Kratz C(2013)A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method Neuro Oncol 15 462-1268

[10] Olbrich H(2010)A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702) Neuro Oncol 12 1257-2638